Wayne State University researchers have identified compounds with a unique molecular template exhibiting reuptake inhibition activity for both at the norepinephrine and serotonin transporters in the CNS. In addition, some of these molecules also exhibit triple reuptake activity for the dopamine, serotonin and norepinephrine transporters. These compounds have shown impressive dual and triple uptake inhibition activity in vitro, have exhibited in vivo antidepressant activity in forced swimming test model in both mice and rats. Lead compounds will be tested in additional in vivo models, and is currently being screened for other CNS receptors under the NIMH PDSP program. These compounds are not derivatives or analogs of any known antidepressant compounds. Because of the atypical structure, it is hypothesized that there will be insignificant interface of these compounds with non-targeted receptors, such as the histamine receptor, which may alleviate the drowsiness and sedation side effects found in other dual active compounds.
Commercial Applications
· Development of Anti-depressants
· Treatment of Attention Deficit Disorders
Patent Status
U.S. and major foreign market patent applications are on file.
Tech ID
03-671